To include your compound in the COVID-19 Resource Center, submit it here.

Incentives to prove cost-benefit

WASHINGTON - Concerted efforts to induce companies to conduct rigorous pharmacoeconomic research on new products in addition to safety and efficacy studies have begun to emerge from industry and Capitol Hill.

Rep. Ron Wyden, D-Ore., calling for a "national campaign to discover the comparative effectiveness of medical technologies," is drafting legislation that would extend patent protection for companies that conduct FDA-approved studies comparing the clinical and pharmacoeconomic effectiveness of their new technologies to existing ones.

To provide other "significant incentives" for voluntary participation, Wyden's proposal also would

Read the full 868 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE